CPL207280

GPR40-free fatty acid receptor 1 (FFA1) agonist

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Bazydlo-Guzenda, Katarzyna: 1 article (10/2021)
2.	Buda, Pawel: 1 article (10/2021)
3.	Dubiel, Krzysztof: 1 article (10/2021)
4.	Dzida, Radoslaw: 1 article (10/2021)
5.	Hucz-Kalitowska, Joanna: 1 article (10/2021)
6.	Kaminska, Bozena: 1 article (10/2021)
7.	Mach, Mateusz: 1 article (10/2021)
8.	Matloka, Mikolaj: 1 article (10/2021)
9.	Pieczykolan, Jerzy: 1 article (10/2021)
10.	Smuga, Damian: 1 article (10/2021)

1.	Hypoglycemia (Reactive Hypoglycemia) 10/01/2021 - "We conclude that CPL207280 is a potent enhancer of glucose-stimulated insulin secretion in animal disease models with no risk of hypoglycemia at therapeutic doses. " 10/01/2021 - "In Wistar Han rats and C57BL6 mice challenged with glucose, CPL207280 stimulated 2.5 times greater insulin secretion without causing hypoglycemia at 10 mg/kg compared with fasiglifam. "
2.	Animal Disease Models 10/01/2021 - "We conclude that CPL207280 is a potent enhancer of glucose-stimulated insulin secretion in animal disease models with no risk of hypoglycemia at therapeutic doses. "
3.	Type 2 Diabetes Mellitus (MODY) 10/01/2021 - "Therefore, we propose the CPL207280 compound as a compelling candidate for type 2 diabetes treatment. " 10/01/2021 - "Therefore, we propose the CPL207280 compound as a novel, glucose-lowering agent, overcoming the unmet medical needs of patients with type 2 diabetes."